-
1.发明公开
公开(公告)号：KR1020150042882A
公开(公告)日：2015-04-22
申请号：KR1020130055866
申请日：2013-05-16
Applicant: 대한민국 (식품의약품안전처장)
CPC classification number: C12Q1/6827 , C12Q2600/106 , C12Q2600/156 , G01N33/15 , G01N33/48
Abstract: 본발명은약물유전형진단방법과약물반응예측방법에관한것으로, 보다상세하게는약물의효과, 이상반응예측, 약동학적반응관련된약물유전자들을조합하여, 많은약물유전형을대용량으로분석가능한최적의분석방법으로분석하고, 그유전형분석결과를이용하여개인의약물반응을예측하는방법에관한것이다. 같은약물이라도사람에따라약물반응이다르게나타나부작용이많이발생하거나, 약효가나타나지않는다. 그러나본 발명을이용하여약물을복용하기전 개인의약물유전형을진단하고약물반응을미리예측하면, 본인에적합한약물의종류, 적정용량을사용할수 있게된다. 본발명으로인하여약물로인한부작용은최소화하고, 약효는최대화하는개인맞춤약물요법을실현할수 있다.
Abstract translation: 本发明涉及药物基因型诊断方法和预测药物应答的方法，更具体地，涉及通过与药物作用，异常应答预测和药物动力学反应相关的药物基因组合来预测药物反应的方法，并分析其 用于分析大容量药物基因型的最佳方法，并使用人们对同一种药物有不同反应的分析结果，因此一些人在服用药物时具有更多的副作用或较少的药物作用。 然而，该方法用于诊断人的药物基因型并预测在服用药物之前对药物的反应，从而使人们能够选择合适的药物和适量的药物并且尽可能减少由药物引起的副作用，同时使药物效应最大化 到个性化药物治疗。
-
公开(公告)号：KR1020130102778A
公开(公告)日：2013-09-23
申请号：KR1020120023880
申请日：2012-03-08
Applicant: 대한민국 (식품의약품안전처장)
CPC classification number: C12Q1/6827 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , G01N33/15 , G01N2800/52
Abstract: PURPOSE: A method for predicting drug response to atomoxetine using the genotype of cytochrome P450 2D6 (CYP2D6) gene is provided to compute a recommended dosage of a drug by each genotype, thereby presenting a proposal on drug approvals in consideration of Korean pharmacogenomics. CONSTITUTION: A method for analyzing the genotype of CYP2D6 gene for predicting drug response to atomoxetine comprises the step of sequencing exon 1 and exon 6 of a gene encoding CYP2D6 from a genomic DNA; detecting single nucleotide polymorphisms (SNPs) in the determined base sequence, wherein 43th base (T) of sequence number 1 (exon 6) is substituted with C (CYP2D6*2) and 100th base (C) of sequence number 2 (exon 1) is substituted with T (CYP2D6*10); and determining if the genotype of CYP2D6 belongs to extensive metabolizer (CYP2D6EM), intermediate metabolizer (CYP2D6IM), or poor metabolizer (CYP2D6PM). [Reference numerals] (AA) Atomoxetine (ng/mL); (BB) Elapse time after injection (hr)
Abstract translation: 目的：提供使用细胞色素P450 2D6（CYP2D6）基因的基因型预测药物对阿托西汀药物反应的方法，以计算每种基因型药物的推荐剂量，从而提出考虑韩国药物基因组学的药物批准建议。 构成：分析CYP2D6基因基因型预测阿托西汀药物反应的方法，包括从基因组DNA测序编码CYP2D6基因的外显子1和外显子6的步骤; 检测确定的碱基序列中的单核苷酸多态性（SNP），其中序列号1（外显子6）的第43位碱基（T）被C（CYP2D6 * 2）和序列号2（外显子1）的第100位碱基（C） 被T（CYP2D6 * 10）取代; 并确定CYP2D6的基因型是否属于广泛代谢者（CYP2D6EM），中间代谢者（CYP2D6IM）或低代谢者（CYP2D6PM）。 （标号）（AA）阿托莫西汀（ng / mL）; （BB）注射后经过时间（小时）
-
公开(公告)号：KR101609725B1
公开(公告)日：2016-04-11
申请号：KR1020130102117
申请日：2013-08-28
Applicant: 대한민국 (식품의약품안전처장)
IPC: G06Q50/22
Abstract: 유전형진단결과를이용한개인별처방방법및 장치가개시되어있다. 개인맞춤형약물정보유도방법은약물유전형검사결과를기반으로개인맞춤약물정보를생성하는단계와상기개인맞춤약물정보를전송하는단계를포함할수 잇되,상기약물유전형검사결과는개인의약물대사에영향을끼칠수 있는유전자정보에대한검사를수행한결과일수 있다. 따라서, 개인별유전자정보에기반하여약물을투여할수 있어약물에의한부작용을방지할수 있다.
-
公开(公告)号：KR1020140048482A
公开(公告)日：2014-04-24
申请号：KR1020120114378
申请日：2012-10-15
Applicant: 대한민국 (식품의약품안전처장)
CPC classification number: C12Q1/6827 , C12Q2600/106 , C12Q2600/156
Abstract: The present invention relates to a method for predicting a drug reaction of tramadol using the genotype of CYP2D6 gene and, more specifically, to a method for predicting metabolic activity of the CYP2D6 enzyme by analyzing single nucleotide polymorphism (SNP) of CYP2D6 gene of Korean people using a primer capable of analyzing SNP and using the analyzed results. Further, the present invention relates to a method for predicting a drug reaction of tramadol by effectively measuring the blood drug concentration of tramadol according to the genotype of CYP2D6 gene. The method of the present invention is useful in selecting a safe drug treatment method and developing and evaluating the personalized drug therapy by predicting a drug reaction for a patient when tramadol is alone administered or co-administered with another drug, through determination of the type of CYP2D6 of the patient. [Reference numerals] (AA) 2.0 times
Abstract translation: 本发明涉及使用CYP2D6基因的基因型预测曲马多的药物反应的方法，更具体地，涉及通过分析韩国人CYP2D6基因的单核苷酸多态性（SNP）来预测CYP2D6酶的代谢活性的方法 使用能够分析SNP并使用分析结果的引物。 此外，本发明涉及一种通过根据CYP2D6基因的基因型有效测定曲马多的药物浓度来预测曲马多的药物反应的方法。 本发明的方法可用于选择安全药物治疗方法，并且通过预测单独施用曲马多或与另一种药物共同施用的患者的药物反应来开发和评估个性化药物治疗，通过确定 患者的CYP2D6。 （标号）（AA）<1.4倍; （BB）<2.0倍; （CC）> 2.0倍
-
公开(公告)号：KR1020130102777A
公开(公告)日：2013-09-23
申请号：KR1020120023879
申请日：2012-03-08
Applicant: 대한민국 (식품의약품안전처장)
CPC classification number: C12Q1/6827 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , G01N33/15 , G01N2800/52
Abstract: PURPOSE: A method for predicting drug response to omeprazole using the genotype of cytochrome p450 2C19 (CYP2C19) gene is provided to analyze the genotype of CYP2C19 gene for predicting drug response to omeprazole and to present a proposal on drug approvals in consideration of Korean pharmacogenomics. CONSTITUTION: A method for analyzing the genotype of CYP2C19 gene for predicting drug response to omeprazole comprises the steps of: acquiring exon 4 and exon 5 of a gene encoding CYP2C19 from genomic DNA and determining each base sequence; detecting single nucleotide polymorphisms (SNPs) of each base sequence, wherein 39th base (G) of sequence number 1 (exon 5) is substituted with A (CYP2C19*2) and 155th base (G) of sequence number 2 (exon 4) is substituted with A (CYP2C19*3); and determining if the genotype of CYP2C19 belongs to extensive metabolizer (EM) group, intermediate metabolizer (IM) group, or poor metabolizer (PM) group using the detected SNP. A method for predicting drug response to omeprazole by each CYP2C19 genotype comprises the steps of: orally administering 20-80 mg of omeprazole to each of the EM, IM, and PM groups; and comparing the area under the concentration-time curve (AUC) by each genotype and computing a dosage of omeprazole by each genotype. [Reference numerals] (AA) Omeprazole (ng/mL); (BB) Elapse time after injecting (hr)
Abstract translation: 目的：提供使用细胞色素p450 2C19（CYP2C19）基因的基因型预测奥美拉唑药物反应的方法，以分析CYP2C19基因的基因型，以预测对奥美拉唑的药物反应，并提出考虑韩国药物基因组学的药物批准建议。 构成：分析CYP2C19基因基因型预测奥美拉唑药物应答的方法，包括以下步骤：从基因组DNA中获得编码CYP2C19基因的外显子4和外显子5，并确定每个碱基序列; 检测每个碱基序列的单核苷酸多态性（SNP），其中序列号1（外显子5）的第39位碱基（G）被序列号2（外显子4）的A（CYP2C19 * 2）和第155位碱基（G）取代为 用A（CYP2C19 * 3）取代; 并使用检测到的SNP确定CYP2C19的基因型是否属于广泛代谢（EM）组，中间代谢者（IM）组或不良代谢者（PM）组。 用于预测每种CYP2C19基因型对奥美拉唑的药物反应的方法包括以下步骤：向每个EM，IM和PM组口服20-80mg奥美拉唑; 并比较各基因型浓度 - 时间曲线下面积（AUC），并计算每种基因型的奥美拉唑剂量。 （AA）奥美拉唑（ng / mL）; （BB）注射后经过时间（小时）
-
Patent Agency Ranking
公开(公告)号：KR1020130093920A
公开(公告)日：2013-08-23
申请号：KR1020120015167
申请日：2012-02-15
Applicant: 대한민국 (식품의약품안전처장)
CPC classification number: C12Q1/6827 , C12Q2600/106 , C12Q2600/156 , C12Q2600/172
Abstract: PURPOSE: A method of analyzing a CYP2C19 genotype for predicting the effect of lansoprazole is provided to supply a haplotype as a drug-metabolizing enzyme activity index of CYP2C19 engaging in a lansoprazole metabolism and be used as an index about the evaluation of medical supplies metabolized by the CYP2C19 and a cross linkage test by grasping the pharmacokinetics characteristic of equivalent drugs. CONSTITUTION: A method of predicting the lansoprazole metabolic activation of a CYP2C19 protein comprises: a step of determining the each base sequence of the promoter of a gene ciphering cytochrome P450 2C19 (CYP2C19) from genomic DNA, exon 4, exon 5, intron 5 and intron 7; a step of detecting the presence of single nucleotide polymorphism (SNP) in the determined each base sequence; a step of identifying the CYP2C19 gene of experimentee with one among haplotype H1-H3 by using the detected SNP; a step of determining whether the identified haplotype belongs to a haplotype combination group consisting of extensive metabolizer (EM), hetero extensive metabolizer (hetero EM) and poor metabolizer (PM) by assembling the identified haplotype with base pairs; and a step of predicting the lansoprazole metabolic activation of the CYP2C19 protein by using the confirmed haplotype combination group. The lansoprazole metabolic activity is the highest when the haplotype combination group belongs to the EM and is lowest when the haplotype combination group belongs to the PM.
Abstract translation: 目的：提供一种分析CYP2C19基因型以预测兰索拉唑效应的方法，以提供单倍型作为参与兰索拉唑代谢的CYP2C19的药物代谢酶活性指数，并用作关于由 CYP2C19和通过抓取等效药物的药代动力学特征进行交联试验。 组成：预测CYP2C19蛋白的兰索拉新陈代谢活化的方法包括：从基因组DNA，外显子4，外显子5，内含子5中确定加密细胞色素P450 2C19（CYP2C19）基因的启动子的每个碱基序列的步骤，以及 内含子7 检测确定的每个碱基序列中单核苷酸多态性（SNP）的存在的步骤; 通过使用检测到的SNP，在单倍型H1-H3中鉴定实验者的CYP2C19基因的步骤; 通过将识别的单倍型与碱基对组合来确定所识别的单倍型是否属于由广泛代谢（EM），杂广泛代谢（异质EM）和不良代谢者（PM）组成的单倍型组合组的步骤; 以及通过使用确认的单倍型组合组预测CYP2C19蛋白的兰索拉唑代谢活化的步骤。 当单倍型组合属于EM时，兰索拉唑代谢活性最高，单倍型组合属于PM时，代谢活性最低。
-
7.发明授权
公开(公告)号：KR101540647B1
公开(公告)日：2015-08-05
申请号：KR1020130055866
申请日：2013-05-16
Applicant: 대한민국 (식품의약품안전처장)
Abstract: 본발명은약물유전형진단방법과약물반응예측방법에관한것으로, 보다상세하게는약물의효과, 이상반응예측, 약동학적반응관련된약물유전자들을조합하여, 많은약물유전형을대용량으로분석가능한최적의분석방법으로분석하고, 그유전형분석결과를이용하여개인의약물반응을예측하는방법에관한것이다. 같은약물이라도사람에따라약물반응이다르게나타나부작용이많이발생하거나, 약효가나타나지않는다. 그러나본 발명을이용하여약물을복용하기전 개인의약물유전형을진단하고약물반응을미리예측하면, 본인에적합한약물의종류, 적정용량을사용할수 있게된다. 본발명으로인하여약물로인한부작용은최소화하고, 약효는최대화하는개인맞춤약물요법을실현할수 있다.
-
公开(公告)号：KR1020150025022A
公开(公告)日：2015-03-10
申请号：KR1020130102117
申请日：2013-08-28
Applicant: 대한민국 (식품의약품안전처장)
IPC: G06Q50/22
Abstract: 유전형 진단 결과를 이용한 개인별 처방 방법 및 장치가 개시되어 있다. 개인 맞춤형 약물 정보 유도 방법은 약물유전형 검사 결과를 기반으로 개인맞춤 약물 정보를 생성하는 단계와 상기 개인 맞춤 약물 정보를 전송하는 단계를 포함할 수 잇되,상기 약물유전형 검사 결과는 개인의 약물 대사에 영향을 끼칠 수 있는 유전자 정보에 대한 검사를 수행한 결과일 수 있다. 따라서, 개인별 유전자 정보에 기반하여 약물을 투여할 수 있어 약물에 의한 부작용을 방지할 수 있다.
Abstract translation: 公开了使用基因型诊断结果的个体处方的方法和装置。 诱导个性化药物信息的方法包括以下步骤：基于药物遗传学测试结果产生个性化药物信息; 并发送个性化药物信息，其中药物遗传学测试结果是通过对影响个体药物代谢的遗传信息进行测试获得的结果。 因此，本发明的方法可以通过基于个体遗传信息施用药物来防止药物的副作用。
-
公开(公告)号：KR1020130102776A
公开(公告)日：2013-09-23
申请号：KR1020120023878
申请日：2012-03-08
Applicant: 대한민국 (식품의약품안전처장)
CPC classification number: C12Q1/6827 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , G01N33/15 , G01N2800/52
Abstract: PURPOSE: A method for predicting drug response to celecoxib using the genotype of cytochrome p450 2C9 (CYP2C9) gene is provided to analyze the genotype of CYP2C9 gene for predicting drug response to celecoxib and to present a proposal on drug approvals in consideration of Korean pharmacogenomics. CONSTITUTION: A method for analyzing the genotype of CYP2C9 gene for predicting drug response to celecoxib comprises the steps of: acquiring exon 2 and exon 7 of a gene encoding CYP2C9 from genomic DNA and sequencing exon 2 and exon 7; detecting single nucleotide polymorphisms (SNPs) in each determined base sequence, wherein 101^th base (T) of sequence number 1 (exon 2) in CYP2C9 is substituted with C (CYP2C9*13) and 114^th base (A) of sequence number 2 (exon 7) in CYP2C9 is substituted with C (CYP2C9*3); and determining if the genotype of CYP2C9 belongs to the extensive metabolizer (EM) group or intermediate metabolizer (IM) group using the detected SNP. A method for predicting drug response to celecoxib by each CYP2C9 genotype comprises the steps of: orally administering 120-250 mg of celecoxib to each of the EM group and the IM group; and comparing the area under the concentration-time curve (AUC) by each genotype and computing a dosage of celecoxib by each genotype. [Reference numerals] (AA) Elapse time after injecting (hr)
Abstract translation: 目的：提供使用细胞色素p450 2C9（CYP2C9）基因的基因型预测药物对塞来昔布药物反应的方法，以分析CYP2C9基因的基因型，以预测药物对塞来昔布的反应，并提出考虑韩国药物基因组学的药物批准建议。 构成：分析CYP2C9基因基因型预测塞来昔布药物反应的方法，包括以下步骤：从基因组DNA和测序外显子2和外显子7获得编码CYP2C9基因的外显子2和外显子7; 检测每个确定的碱基序列中的单核苷酸多态性（SNP），其中CYP2C9中序列号1（外显子2）的第101位碱基（T）被C（CYP2C9 * 13）和第114位碱基（A）序列替代 CYP2C9中第2（外显子7）被C（CYP2C9 * 3）取代; 并使用检测到的SNP确定CYP2C9的基因型是否属于广泛代谢（EM）组或中间代谢（IM）组。 预测每种CYP2C9基因型对塞来昔布的药物反应的方法包括以下步骤：向EM组和IM组口服120-250mg塞来昔布; 并比较每种基因型浓度 - 时间曲线下面积（AUC），并计算每种基因型的塞来昔布剂量。 （标号）（AA）注射后经过时间（hr）
-
公开(公告)号：KR101301872B1
公开(公告)日：2013-08-30
申请号：KR1020120015167
申请日：2012-02-15
Applicant: 대한민국 (식품의약품안전처장)
Abstract: 본 발명은 시토크롬 P450 2C19(CYP2C19)를 암호화하는 유전자의 일배체형 분석방법, 분석키트 및 이를 이용한 CYP2C19 효소의 활성예측방법에 관한 것이다. 좀 더 구체적으로, 본 발명은 한국인의 CYP2C19 유전자에 위치한 기존에 알려진 단일염기다형성(SNP)에 더하여 신규의 SNP를 추가 발굴하여, 특정 일배체형(Haplotype) 정보를 확보하였는 바, 이 일배체형을 분석할 수 있는 프라이머를 이용한 일배체형 분석방법, 분석키트 및 이를 이용하여 CYP2C19 효소의 활성을 예측하는 방법에 관한 것이다. 본 발명에 의하면, 란소프라졸 대사에 관여하는 CYP2C19의 약물대사효소 활성 지표로서 일배체형을 제공할 수 있으며, 유사약물의 약동 및 약력학적 특성을 파악함으로써 CYP2C19에 의해 대사되는 의약품의 평가 및 가교시험에 대한 지표로서 활용할 수 있다.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.021 seconds)
